Status: Recruiting
Phase I Study of JYP0322 in ROS1 Fusion-Positive Solid Tumors
An open, non-randomized, multicenter, single-arm dose-escalation design, phase 1 trial to study the safety, tolerability, pharmacokinetics and efficacy of JYP0322 in patients with ROS1+ locally advanced/metastatic solid tumors .
Participants needed: 101
Trial details
Phase: Phase 1Age: 18+Biological sex: AllType: InterventionalSponsor: Guangzhou JOYO Pharma Co., LtdUpdated: Jul 14, 2025Locations: 1
Eligibility criteria
Adult patients age 18 years or older. [+4]
Current participation in another therapeutic clinical trial. [+4]